Cymbalta approved for fibromyalgia
The antidepressant Cymbalta (duloxetine), marketed by Lilly, has received FDA approval for the treatment of fibromyalgia. While certain antidepressants are considered first-line therapy for fibromyalgia, most notably the tricyclic antidepressants such as amitriptyline, none had been approved by the FDA for this use until now. Cymbalta belongs to a newer class of antidepressants known collectively as serotonin and norepinephrine reuptake inhibitors (SNRIs), which are somewhat similar to the serotonin reuptake inhibitors (SSRIs), of which Prozac, also marketed by Lilly, is the most widely known. Cymbalta is already marketed for the treatment of depression, anxiety and for pain associated with diabetic peripheral neuropathy. It was first approved for U.S. marketing in 2004.
Cymbalta is now the second drug approved by the FDA for the treatment of fibromyalgia. Almost exactly one year ago the FDA approved Pfizer’s Lyrica (pregabalin) and I alerted readers to that approval in a posting; at […]
Original post by natalieb and weightlossopinions.com
